News

The combination given before lymph node dissection and response-driven adjuvant therapy reduced the risk for recurrence, progression, or death in stage III melanoma.

Adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Triplet therapies containing belantamab mafodotin, pomalidomide, and dexamethasone may address an unmet need for relapsed/refractory multiple myeloma.

The survival benefit obtained from consolidation treatment with durvalumab after concurrent chemoradiation may change the standard of care for limited-stage small cell lung cancer.

Compared with placebo, osimertinib after definitive chemoradiotherapy improved progression-free survival in locally advanced, EGFR-mutated non–small cell lung cancer.

Patients with refractory EGFR-mutated, advanced non-small lung cancer had improved responses with low rates of adverse effects with subcutaneous amivantamab vs its intravenous formulation.

Updated data from the MANIFEST-2 study support a paradigm shift in the treatment of JAK inhibitor–naive patients with myelofibrosis.

These data from the COMBI-AD trial represent the longest follow-up to date of adjuvant treatment for stage III melanoma.

Frontline amivantamab plus lazertinib outperformed osimertinib regarding progression-free survival in patients with high-risk EGFR-mutant non-small cell lung cancer.

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia.

Lorlatinib, compared with crizotinib, prolonged PFS and improved time to intracranial progression in ALK-positive non–small cell lung cancer.

This marks the only CAR T-cell therapy approved by the FDA for 4 subtypes of non-Hodgkin lymphoma.

Patients with advanced clear cell renal cell carcinoma who received salvage treatment with nivolumab plus ipilimumab after progressing on nivolumab alone had significant treatment-free survival rates.

Selpercatinib was granted accelerated approval from the FDA for patients aged 2 years and older with thyroid cancer or solid tumors with RET mutations.

Six-year administration of imatinib maintenance therapy—compared with the standard 3 years—improved disease-free survival in gastrointestinal stromal tumors.

Oncology nurses can educate patients about the availability of pre-exposure prophylaxis for preventing COVID-19.

Community urology practices have routinely used darolutamide in both doublet and triplet regimens to treat metastatic hormone-sensitive prostate cancer.

Nadofaragene firadenovec resulted in durable antitumor activity at 5 years in patients with BCG-unresponsive NMIBC either with carcinoma in situ or papillary disease.

A breakthrough device designation has been granted by the FDA to Teal Wand, an at-home screening test for cervical cancer.

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

Postmenopausal women who had undergone hysterectomy and received treatment with conjugated equine estrogen alone had an increased incidence of ovarian cancer and mortality rates.

Most survivors of stage I-III breast cancer who attempted pregnancy succeeded, though there were certain factors that seemed to increase the chance of conception.

Using an artificial intelligence-based navigation tool to contact patients who missed their colonoscopy appointment may help them reschedule and potentially attend a new appointment.

Converting operating rooms into those that are able to filter surgical smoke and biological contaminants can make workplaces safer for nurses and other health care staff.

Adding capivasertib to fulvestrant was shown to improve the time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Uproleselan plus chemotherapy missed the overall survival end point in the phase 3 trial assessing the combination in patients with relapsed/refractory acute myeloid leukemia.

Compared with physician’s choice of treatment, trastuzumab deruxtecan exhibited superior long-term survival and response rates in patients with HER2-positive breast cancer.

Oncology nurses can discuss dose modifications for common smoking cessation agents with patients and providers to improve smoking cessation rates.